Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 07, 2024 16:10 ET | Source: Evoke Pharma, Inc.

Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024

SOLANA BEACH, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an...
February 14, 2024 07:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Announces Closing of $7.5 Million Public Offering

SOLANA BEACH, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
February 09, 2024 07:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million

SOLANA BEACH, Calif., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
November 27, 2023 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent

SOLANA BEACH, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
November 14, 2023 08:30 ET | Source: Evoke Pharma, Inc.

United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI

SOLANA BEACH, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
November 09, 2023 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Reports Third Quarter 2023 Financial Results

38% Revenue Increase Compared to Q2 2023; 88% Increase Year-Over-Year Seventh Straight Prescription Fill Increase Since Q1 2022 21% Increase Compared to Q2 2023; 95% Increase Year-Over-Year ...
October 31, 2023 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023

SOLANA BEACH, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
October 18, 2023 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma’s Abstract Entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” to Be Presented at The American College of Gastroenterology (ACG) 2023 Annual Meeting

SOLANA BEACH, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
September 14, 2023 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI®

SOLANA BEACH, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
August 10, 2023 08:30 ET | Source: Evoke Pharma, Inc.

Evoke Pharma Reports Second Quarter 2023 Financial Results

40% revenue growth compared to Q1 2023 34% increase in prescription fills compared to Q1 2023 Presented industry-leading real-world healthcare utilization data supporting the benefits of GIMOTI...